Immunotherapy and chemotherapy before surgery for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs with chemotherapy, with or without a targeted therapy pill, given before surgery for advanced ovarian cancer. It aims to shrink tumors to make surgery more effective and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer (stage III or IV) that is of a specific type (high-grade serous or endometrioid).
- You have not had any prior treatment for this cancer (like chemotherapy, radiation, or surgery).
- You are willing to undergo genetic testing for BRCA and HRD status.
- Your doctor thinks you are not a good candidate for immediate surgery, or you cannot tolerate it.
- You have at least one tumor that can be measured on scans.
- Your overall health is good (ECOG score 0-1 for one group, or 2 for another group).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You are not pregnant, not breastfeeding, and will use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, bevacizumab, and chemotherapy given before surgery for advanced ovarian cancer. The goal is to shrink tumors to make surgery more effective and potentially improve outcomes.
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
This trial tests two oral medications, pamiparib and surufatinib, given before surgery to shrink advanced ovarian cancer. The goal is to make surgery more successful and potentially improve outcomes for patients who cannot have surgery right away.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial tests a combination of three targeted drugs (olaparib, durvalumab, and bevacizumab) as a first treatment for advanced ovarian cancer. It aims to shrink tumors before possible surgery, potentially improving outcomes.
Hear when a new Ovarian Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.